- Conditions
- Multiple System Atrophy
- Interventions
- AAV2-GDNF gene therapy, Sham (Placebo) Surgery
- Biological · Procedure
- Lead sponsor
- Brain Neurotherapy Bio, Inc.
- Industry
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 7
- States / cities
- Irvine, California • Boca Raton, Florida • Boston, Massachusetts + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 38
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy Adult
- Interventions
- [¹⁸F]MODAG-009 PET Imaging
- Drug
- Lead sponsor
- MODAG GmbH
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Multiple System Atrophy - Parkinsonian Subtype (MSA-P), Multiple System Atrophy - Cerebellar Subtype (MSA-C)
- Interventions
- Not listed
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
- Interventions
- Ampreloxetine, Placebo
- Drug
- Lead sponsor
- Theravance Biopharma
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 26
- States / cities
- Scottsdale, Arizona • Fountain Valley, California • La Jolla, California + 21 more
- Conditions
- Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Pure Autonomic Failure, Parkinson Disease, Hypotension, Orthostatic, Orthostatic Hypotension, Pure Autonomic Failure With Orthostatic Hypotension, Parkinson Disease With Orthostatic Hypotension
- Interventions
- TD-9855, Placebo
- Drug
- Lead sponsor
- Theravance Biopharma
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 6
- States / cities
- Long Beach, California • Farmington Hills, Michigan • Berlin, New Jersey + 3 more
- Conditions
- Multiple System Atrophy
- Interventions
- ATH434
- Drug
- Lead sponsor
- Alterity Therapeutics
- Industry
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Multiple System Atrophy
- Interventions
- TEV-56286, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Industry
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 349 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 19
- States / cities
- La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 15 more
- Conditions
- Multiple System Atrophy, MSA
- Interventions
- AZD3241, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 8
- States / cities
- Stanford, California • New Haven, Connecticut • Tampa, Florida + 4 more
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy, Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
- Interventions
- Placebo, Droxidopa
- Drug
- Lead sponsor
- Chelsea Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 14
- States / cities
- Huntsville, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 11 more
- Conditions
- Multiple System Atrophy
- Interventions
- Not listed
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 29 participants
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension, Parkinson's Disease, Multiple Systems Atrophy, Pure Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
- Interventions
- Droxidopa, Placebo
- Drug
- Lead sponsor
- Chelsea Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 3
- States / cities
- New York, New York • Charlotte, North Carolina • Milwaukee, Wisconsin
- Conditions
- Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
- Interventions
- Not listed
- Lead sponsor
- The Parkinson Study Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Multiple System Atrophy
- Interventions
- intravenous immunoglobulin (IVIg)
- Drug
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- PSP, CBD, PCA, LPA, Semantic Dementia, Semantic Aphasia, Behavioral Variant of Frontotemporal Dementia, FTD, PPA, Apraxia of Speech, MSA - Multiple System Atrophy, Parkinson Disease
- Interventions
- C-11 PiB, AV1451 Tau, C-11 ER176
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2050
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Multiple System Atrophy
- Interventions
- Amlenetug, Placebo
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 401 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • San Francisco, California + 18 more
- Conditions
- Multiple System Atrophy
- Interventions
- HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells
- Biological
- Lead sponsor
- Hope Biosciences Research Foundation
- Industry
- Eligibility
- 18 Years to 85 Years
- U.S. locations
- 1
- States / cities
- Sugar Land, Texas
- Conditions
- PSP, PSP - Progressive Supranuclear Palsy, Corticobasal Syndrome, Corticobasal Syndrome(CBS), Corticobasal Degeneration Syndrome, Corticobasal Degeneration, Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS), MSA, MSA - Multiple System Atrophy, MSA-C, Multiple System Atrophy, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Multiple System Atrophy - Cerebellar Subtype (MSA-C), Multiple System Atrophy - Parkinsonian Subtype (MSA-P), Multiple System Atrophy, Cerebellar Type, Multiple System Atrophy, Parkinsonian Type, Progressive Supranuclear Palsy, Progressive Supranuclear Palsy(PSP), Progressive Supranuclear Palsy (PSP)
- Interventions
- Whole genome sequencing will be performed at the NIH
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 35 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Progressive Supranuclear Palsy, Parkinson Disease, MSA - Multiple System Atrophy
- Interventions
- Not listed
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Boston, Massachusetts
- Conditions
- Parkinson's Disease, Parkinsonism, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, Shy-Drager Syndrome, Corticobasal Degeneration, Dementia With Lewy Bodies, Pick Disease, Olivopontocerebellar Atrophies
- Interventions
- Not listed
- Lead sponsor
- Bastyr University
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2030
- U.S. locations
- 1
- States / cities
- Kenmore, Washington
- Conditions
- Essential Tremor, Multiple System Atrophy, Corticobasal Degeneration, Supranuclear Palsy, Progressive, Parkinson Disease
- Interventions
- Not listed
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Multiple System Atrophy (MSA)
- Interventions
- Not listed
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension
- Interventions
- ampreloxetine, Placebo
- Drug
- Lead sponsor
- Theravance Biopharma
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 23
- States / cities
- Sun City, Arizona • Long Beach, California • Palo Alto, California + 19 more
- Conditions
- Multiple System Atrophy (MSA), Healthy Adult, Parkinson Disease
- Interventions
- [¹⁸F]MODAG-009 PET imaging
- Drug
- Lead sponsor
- MODAG GmbH
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- MSA
- Interventions
- Autologous Mesenchymal Stem Cells
- Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota